CytomX Therapeutics, Inc. Operating Leases, Rent Expense, Net
CytomX Therapeutics, Inc. (CTMX) reported Operating Leases, Rent Expense, Net of $4.20 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeasesRentExpenseNet · last filed 2019-02-27
- CytomX Therapeutics, Inc. operating leases, rent expense, net for the quarter ending 2017-12-31 was $1.00M, a 23.08% decline year-over-year.
- CytomX Therapeutics, Inc. operating leases, rent expense, net for the quarter ending 2017-09-30 was $1.10M, a 266.67% increase year-over-year.
- CytomX Therapeutics, Inc. operating leases, rent expense, net for the quarter ending 2017-06-30 was $1.10M, a 266.67% increase year-over-year.
- CytomX Therapeutics, Inc. operating leases, rent expense, net for the quarter ending 2017-03-31 was $1.10M.
- CytomX Therapeutics, Inc. operating leases, rent expense, net for fiscal 2018 was $4.20M, a 0.00% change from fiscal 2017.
- CytomX Therapeutics, Inc. operating leases, rent expense, net for fiscal 2017 was $4.20M, a 133.33% increase from fiscal 2016.
- CytomX Therapeutics, Inc. operating leases, rent expense, net for fiscal 2016 was $1.80M, a 100.00% increase from fiscal 2015.
- CytomX Therapeutics, Inc. operating leases, rent expense, net for fiscal 2015 was $900.00K, a 12.50% increase from fiscal 2014.
| Period end | Operating Leases, Rent Expense, Net 3 month | Operating Leases, Rent Expense, Net 3 month as first filed | Operating Leases, Rent Expense, Net 6 month | Operating Leases, Rent Expense, Net 6 month as first filed | Operating Leases, Rent Expense, Net 9 month | Operating Leases, Rent Expense, Net 9 month as first filed | Operating Leases, Rent Expense, Net 12 month | Operating Leases, Rent Expense, Net 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | $4.20M 10-K · filed 2019-02-27 | |||||||
| 2017-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $2.10M derived: sum of 2 quarters · filed 2019-02-27 | $3.20M derived: sum of 3 quarters · filed 2019-02-27 | $4.20M 10-K · filed 2019-02-27 | ||||
| 2017-09-30 | $1.10M 10-Q · filed 2017-11-07 | $2.20M derived: sum of 2 quarters · filed 2017-11-07 | $3.20M 10-Q · filed 2017-11-07 | $4.60M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-06-30 | $1.10M 10-Q · filed 2017-08-07 | $2.10M 10-Q · filed 2017-08-07 | $3.50M derived: sum of 3 quarters · filed 2019-02-27 | $3.80M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-03-31 | $1.10M 10-Q · filed 2017-05-05 | $2.40M derived: sum of 2 quarters · filed 2019-02-27 | $2.70M derived: sum of 3 quarters · filed 2019-02-27 | $3.00M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $1.60M derived: sum of 2 quarters · filed 2019-02-27 | $1.90M derived: sum of 3 quarters · filed 2019-02-27 | $1.80M 10-K · filed 2019-02-27 | ||||
| 2016-09-30 | $300.00K 10-Q · filed 2017-11-07 | $255.00K 10-Q · filed 2016-11-03 | $600.00K derived: sum of 2 quarters · filed 2017-11-07 | $500.00K 10-Q · filed 2017-11-07 | $505.00K 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $300.00K 10-Q · filed 2017-08-07 | $300.00K 10-Q · filed 2017-08-07 | $469.00K 10-Q · filed 2016-08-03 | |||||
| 2015-12-31 | $195.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $431.00K derived: sum of 2 quarters · filed 2018-03-07 | $900.00K 10-K · filed 2018-03-07 | $940.00K 10-K · filed 2016-03-07 | ||||
| 2015-09-30 | $236.00K 10-Q · filed 2016-11-03 | $705.00K 10-Q · filed 2016-11-03 | ||||||
| 2015-03-31 | $235.00K 10-Q · filed 2016-05-06 | $433.00K derived: sum of 2 quarters · filed 2017-03-02 | ||||||
| 2014-12-31 | $198.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $800.00K 10-K · filed 2017-03-02 | $836.00K 10-K · filed 2016-03-07 | |||||
| 2014-09-30 | $602.00K 10-Q · filed 2015-11-23 | |||||||
| 2013-12-31 | $529.00K 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |